News

An analysis of the COPDGene Study presented at ATS 2023 suggests presence of mucus plugs in medium- to large-sized airways were associated with an increased risk of mortality in adjusted models.

AD109 shows the potential to address an unmet need in obstructive sleep apnea treatment.

RBX2660 was the first ever live microbiota therapeutic to gain approval from the FDA for rCDI.

However, trends in the incidence of eye injuries associated with non-powder guns should be interpreted with caution as COVID-19 may have interfered with epidemiological trends.

During this interview segment, Friedman further explored the topics in his presentation on fixing disparities in care for eczema patients through teledermatology.

The June 22, 2023 PDUFA date for obeticholic acid 25 mg oral tablets for the treatment of precirrhotic liver fibrosis appears to be in jeopardy after a May 23, 2023 meeting of the FDA's Gastrointestinal Drugs Advisory Committee.

The structure of the retinal vasculature may be able to predict the initial treatment response to intravitreal therapy in patients with treatment-naïve nAMD.

The study revealed that healthcare workers with psychiatric disorders had slightly lower Anti-SARS-CoV-2-Spike IgG levels before their third COVID-19 vaccination, but this effect was mediated by age and body mass index.

The long-awaited FDA approval follows data that demonstrated about 70% wound closure by 6 months in dystrophic epidermolysis bullosa patients treated with B-VEC.

Announced by Bausch + Lomb and Novaliq, the prescription eye drop for DED is the first and only drop that directly targets tear evaporation, with approval based on results from 2 pivotal phase 3 trials.

Announced by the US FDA on May 19, 2023, the clearance of the iLet ACE Pump and the iLet Dosing Decision Software, when combined with a compatible CGM, will form the iLet Bionic Pancreas.

Dr. Levine talks with Marketa Wills, MD, about the role of the payer in medicine.

In this episode of Don’t Miss a Beat, hosts sit down at ESC HFA to discuss key takeaways from the ACC's expert clinical decision pathway and preview HFpEF data scheduled to be presented during the meeting.

An economic evaluation of the SCORE2 trial indicates aflibercept treatment was unlikely to meet most accepted standards of cost-effectiveness, due to little difference in visual acuity outcomes and a large cost differential compared with bevacizumab.

Children with autism experience higher frequencies of restless sleep, circadian rhythm disorder, and insomnia, indicating the need for targeted sleep evaluation.

Cost-effective smartphone-based fundus imaging systems may be effective for the detection of treatment-requiring ROP, and help increase the global capacity for ROP screening.

The increased use of tobacco-free nicotine products highlights the need for physicians to stay informed about nicotine pouches and be prepared for discussions with their patients.

For the maintenance trial, 42% and 55% of patients treated with upadacitinib 15 mg and 30 mg achieved clinical remission at week 52, compared to 14% of the placebo group.

In this episode, hosts sit down for an in-depth discussion of the 11 person-centered algorithms for clinical decision-making featured in the AACE's 2023 Comprehensive Type 2 Diabetes Management Algorithm.

Guselkumab is currently being evaluated as a treatment for both ulcerative colitis and Crohn's disease.

Relocation led to a reduction in asthma exacerbations, exceeding the effect of inhaled corticosteroids, and was similar to biologic agents.

A recent analysis suggests that incorporating retinal and choroidal microvascular metrics may improve the identification of eyes with no diabetic retinopathy from those with DR.

An analysis of data from donors within the UNOS network suggests donor hearts from patients who were COVID-19 who were COVID-19 positive could place patients at increased risk of mortality.

A redo surgery often improves the quality of life in a number of ways for patients with ulcerative colitis.

A lack of a significant refractive error and visiting an optometrist rather than an ophthalmologist were factors associated with a missed diagnosis of primary open-angle glaucoma, according to a recent analysis.

In this interview, Friedman described his conference presentation on treating atopic dermatitis through telemedicine to address the disparities in care that are visible around the world.

The LYNX drug development platform is able to deliver drug consistently, while minimizing peaks and troughs of drug levels compared to daily medicine.

In this interview, Hebert discussed recent positive topline results from the ADORING 1 trial on tapinarof cream for atopic dermatitis patients aged 2 years and older.